[{"id":"e6bd139e-7d5b-486d-888f-481618f10fed","acronym":"LONCA","url":"https://clinicaltrials.gov/study/NCT05270057","created_at":"2022-03-08T16:52:28.981Z","updated_at":"2024-07-02T16:34:59.173Z","phase":"Phase 1","brief_title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","source_id_and_acronym":"NCT05270057 - LONCA","lead_sponsor":"Medical College of Wisconsin","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-06-04"},{"id":"0ac2e887-fadd-46a5-ab74-27b50f021611","acronym":"OPTIMAL\u003e60","url":"https://clinicaltrials.gov/study/NCT01478542","created_at":"2021-01-18T06:10:12.656Z","updated_at":"2024-07-02T16:35:07.367Z","phase":"Phase 3","brief_title":"OPTIMAL\u003e60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine","source_id_and_acronym":"NCT01478542 - OPTIMAL\u003e60","lead_sponsor":"Universität des Saarlandes","biomarkers":" ALK • CD20","pipe":" | ","alterations":" ALK positive","tags":["ALK • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Marqibo (vincristine liposomal)"],"overall_status":"Completed","enrollment":" Enrollment 1152","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-04-26"},{"id":"d9205d85-be27-4b6c-84a5-c85c6627b25a","acronym":"NCI-2018-01198","url":"https://clinicaltrials.gov/study/NCT03136146","created_at":"2021-01-18T15:27:28.397Z","updated_at":"2024-07-02T16:35:12.329Z","phase":"Phase 2","brief_title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","source_id_and_acronym":"NCT03136146 - NCI-2018-01198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-03-29"},{"id":"790ce6b7-44f9-4447-9759-09e1b262a8bf","acronym":"ECOG-ACRIN EA9152","url":"https://clinicaltrials.gov/study/NCT03504644","created_at":"2021-01-18T17:15:14.614Z","updated_at":"2024-07-02T16:35:44.927Z","phase":"Phase 1/2","brief_title":"Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03504644 - ECOG-ACRIN EA9152","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Marqibo (vincristine liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-06-23"},{"id":"9498000e-e76e-48a5-8403-624b16296410","acronym":"","url":"https://clinicaltrials.gov/study/NCT00567567","created_at":"2021-01-18T02:04:15.818Z","updated_at":"2024-07-02T16:36:11.330Z","phase":"Phase 3","brief_title":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","source_id_and_acronym":"NCT00567567","lead_sponsor":"Children's Oncology Group","biomarkers":" CD8 • MYCN • UGT1A1 • CD4","pipe":" | ","alterations":" MYCN amplification • UGT1A1*1*1","tags":["CD8 • MYCN • UGT1A1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • topotecan • melphalan • Marqibo (vincristine liposomal) • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 665","initiation":"Initiation: 11/05/2007","start_date":" 11/05/2007","primary_txt":" Primary completion: 02/27/2015","primary_completion_date":" 02/27/2015","study_txt":" Completion: 03/31/2022","study_completion_date":" 03/31/2022","last_update_posted":"2022-04-28"},{"id":"4e2624b6-f37c-4cef-a490-8ac1b580742e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03851081","created_at":"2021-01-18T19:00:50.012Z","updated_at":"2024-07-02T16:36:17.836Z","phase":"Phase 1b/2","brief_title":"Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03851081","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin) • Marqibo (vincristine liposomal)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 01/21/2023","primary_completion_date":" 01/21/2023","study_txt":" Completion: 01/21/2024","study_completion_date":" 01/21/2024","last_update_posted":"2022-01-28"},{"id":"45027f83-3b0a-45d5-b618-4e8c0da85c7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01445535","created_at":"2021-01-18T05:59:48.054Z","updated_at":"2024-07-02T16:36:21.558Z","phase":"Phase 1","brief_title":"Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas","source_id_and_acronym":"NCT01445535","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • CD2","pipe":" | ","alterations":" ALK positive","tags":["ALK • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Marqibo (vincristine liposomal) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 01/13/2009","start_date":" 01/13/2009","primary_txt":" Primary completion: 04/01/2011","primary_completion_date":" 04/01/2011","study_txt":" Completion: 10/22/2020","study_completion_date":" 10/22/2020","last_update_posted":"2021-11-03"},{"id":"17432d8c-7e99-4ab1-907c-c0a7494ecdcb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01851551","created_at":"2021-01-18T08:15:58.988Z","updated_at":"2024-07-02T16:36:51.890Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL","source_id_and_acronym":"NCT01851551","lead_sponsor":"Acrotech Biopharma LLC","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Marqibo (vincristine liposomal)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2001","start_date":" 09/01/2001","primary_txt":" Primary completion: 04/01/2004","primary_completion_date":" 04/01/2004","study_txt":" Completion: 04/01/2005","study_completion_date":" 04/01/2005","last_update_posted":"2020-01-03"},{"id":"0801a37d-ac3b-4a5e-9b77-5d3a907cee08","acronym":"","url":"https://clinicaltrials.gov/study/NCT00098839","created_at":"2021-01-18T00:18:44.126Z","updated_at":"2024-07-02T16:37:15.583Z","phase":"Phase 2","brief_title":"Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)","source_id_and_acronym":"NCT00098839","lead_sponsor":"Children's Oncology Group","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Marqibo (vincristine liposomal) • Epratucyn (epratuzumab) • Neupogen (filgrastim) • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 02/01/2005","start_date":" 02/01/2005","primary_txt":" Primary completion: 04/01/2011","primary_completion_date":" 04/01/2011","study_txt":" Completion: 04/01/2011","study_completion_date":" 04/01/2011","last_update_posted":"2017-12-12"}]